Protecting the health of patients at cardiovascular and cerebrovascular risk - Boehringer-Ingelheim's South African journey: from fibrinolytics (Actilyse and Metalyse) to the protective anti-hypertensive (Micardis).
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D004345:Drug Industry; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D018570:Risk Assessment; D013019:South Africa; D000077333:Telmisartan; D000077785:Tenecteplase; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D000077333:Telmisartan; D000077785:Tenecteplase